CIK 0001855175 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Contineum Therapeutics, Inc.
Sign in to watch- Ticker
- CTNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 271467257
- Phone
- (858) 333-5280
- Business address
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,142
- in 1 filing, $41K under 10b5-1 plans
Net −$41,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-29 | Watkins Tim CMO & Head of Development | Option exercise 10b5-1 | +3,611 | $4.50 | $16K | 3,611 |
| 2025-12-29 | Watkins Tim CMO & Head of Development | Sale 10b5-1 | −3,611 | $12.06 | $44K | 0 |
| 2025-12-29 | Watkins Tim CMO & Head of Development | Option exercise · Stock Option (right to buy) 10b5-1 | −3,611 | 256,389 | ||
| 2025-12-23 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −4,170 | $12.23 | $51K | 164,392 |
| 2025-06-26 | Boyce Sarah Director | Grant or award · Stock Option (right to buy) | +14,750 | 14,750 | ||
| 2025-06-26 | Schimmelpennink Evert B. Director | Grant or award · Stock Option (right to buy) | +14,750 | 14,750 | ||
| 2025-06-26 | Brady Todd R. Director | Grant or award · Stock Option (right to buy) | +14,750 | 14,750 | ||
| 2025-06-26 | Ignelzi Troy A. Director | Grant or award · Stock Option (right to buy) | +14,750 | 14,750 | ||
| 2025-06-26 | Lyons-Williams Lori Director | Grant or award · Stock Option (right to buy) | +14,750 | 14,750 | ||
| 2025-06-26 | Ware Olivia C Director | Grant or award · Stock Option (right to buy) | +14,750 | 14,750 | ||
| 2025-06-26 | Miralles Gines Diego Director | Grant or award · Stock Option (right to buy) | +14,750 | 14,750 | ||
| 2025-04-28 | Watkins Tim CMO & Head of Development | Grant or award · Stock Option (right to buy) | +260,000 | 260,000 | ||
| 2025-04-28 | Watkins Tim CMO & Head of Development | Grant or award · Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2025-03-14 | Miralles Gines Diego Director | Grant or award · Stock Option (right to buy) | +29,500 | 29,500 | ||
| 2025-01-31 | Healy John Stephen General Counsel and Corp Sec | Grant or award · Stock Option (right to buy) | +63,589 | 63,589 | ||
| 2025-01-31 | Slover Peter T Chief Financial Officer | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2025-01-31 | Lorrain Daniel S. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2025-01-31 | Lorrain Daniel S. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +3,700 | 3,700 | ||
| 2025-01-31 | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2025-01-31 | Stengone Carmine N. CEO and President | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 |
Page 5 of 7 · 139 trades